retatrutide facts A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide 5mg - MEDICA DEPOT

MOTS-c Vials Intermittent protocol: 5 mg per injection, 2-3x weekly

A serve of nuts is 30g, or a handful

Tirzepatide (Mounjaro/Zepbound) activates GLP-1 and GIP receptors

PDUFA Date and Launch If the NDA is filed Q4 2026, expect FDA action around late 2027 (priority review) or Q1 2028 (standard review), with commercial launch following 13 months later for manufacturing and distribution setup

Already reported (and cleared primary endpoints): TRIUMPH-1 pivotal general obesity (May 21, 2026) 28.3% weight loss at 80 weeks, 30.3% at 104 weeks in a pre-specified extension

In some cases, patients may be transitioned to an alternative medication that is safe for pregnancy and can be used to help manage their metabolic health during pregnancy